EP1581167A4 - COMPOSITIONS AND METHODS FOR TREATING PARKINSON AND TARDIVER DYSKINESIA - Google Patents

COMPOSITIONS AND METHODS FOR TREATING PARKINSON AND TARDIVER DYSKINESIA

Info

Publication number
EP1581167A4
EP1581167A4 EP03763398A EP03763398A EP1581167A4 EP 1581167 A4 EP1581167 A4 EP 1581167A4 EP 03763398 A EP03763398 A EP 03763398A EP 03763398 A EP03763398 A EP 03763398A EP 1581167 A4 EP1581167 A4 EP 1581167A4
Authority
EP
European Patent Office
Prior art keywords
parkinson
disease
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03763398A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1581167A2 (en
Inventor
Jodi Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Research Group LLC
Original Assignee
Alpha Research Group LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/192,414 external-priority patent/US20020198231A1/en
Application filed by Alpha Research Group LLC filed Critical Alpha Research Group LLC
Publication of EP1581167A2 publication Critical patent/EP1581167A2/en
Publication of EP1581167A4 publication Critical patent/EP1581167A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03763398A 2002-07-09 2003-07-09 COMPOSITIONS AND METHODS FOR TREATING PARKINSON AND TARDIVER DYSKINESIA Withdrawn EP1581167A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/192,414 US20020198231A1 (en) 1999-07-13 2002-07-09 Compositions and methods for the treatment of Parkinson's disease
US192414 2002-07-09
US47974803P 2003-06-19 2003-06-19
US479748P 2003-06-19
PCT/US2003/021463 WO2004004660A2 (en) 2002-07-09 2003-07-09 Compositions and methods for the treatment of parkinson’s disease and tardive dyskinesias

Publications (2)

Publication Number Publication Date
EP1581167A2 EP1581167A2 (en) 2005-10-05
EP1581167A4 true EP1581167A4 (en) 2008-10-29

Family

ID=30117814

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03763398A Withdrawn EP1581167A4 (en) 2002-07-09 2003-07-09 COMPOSITIONS AND METHODS FOR TREATING PARKINSON AND TARDIVER DYSKINESIA

Country Status (5)

Country Link
EP (1) EP1581167A4 (https=)
JP (1) JP2006514917A (https=)
AU (1) AU2003248893A1 (https=)
CA (1) CA2531810A1 (https=)
WO (1) WO2004004660A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
RU2008135762A (ru) * 2006-02-16 2010-03-27 Де МакЛин Хоспитал Корпорейшн (US) Способы и композиции для лечения болезни паркинсона
AU2010256541B2 (en) * 2009-06-03 2016-03-10 Marquette University Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
CN103180297A (zh) * 2009-12-11 2013-06-26 基因密码公司 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法
CN113354581B (zh) * 2020-03-06 2023-06-20 华南理工大学 手性氯喹及其磷酸盐的制备方法及其应用
CN113527201A (zh) * 2020-04-14 2021-10-22 瀚海新拓(杭州)生物医药有限公司 光学活性氯喹和羟氯喹及其类似物、其制备方法、组合物和用途
WO2025213007A1 (en) * 2024-04-04 2025-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services S-hydroxychloroquine, optionally with tauroursodeoxycholic acid and/or 3,3'-diindolylmethane, for treating and/or preventing neurological disorders
CN119924299B (zh) * 2025-04-08 2025-06-06 内蒙古农业大学 羊精子内源铁死亡抑制蛋白保护剂及保护方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428199A1 (de) * 1994-08-09 1996-02-15 Univ Ludwigs Albert Verwendung von Flunitrazepam und/oder Chloroquin zur Behandlung von Spätdyskinesien
WO2001003649A2 (en) * 1999-07-13 2001-01-18 Alpha Research Group, Llc Compositions and methods for the treatment of parkinson's disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430039A (en) * 1990-09-28 1995-07-04 Cephalon, Inc. Treatment of neurological disorders
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428199A1 (de) * 1994-08-09 1996-02-15 Univ Ludwigs Albert Verwendung von Flunitrazepam und/oder Chloroquin zur Behandlung von Spätdyskinesien
WO2001003649A2 (en) * 1999-07-13 2001-01-18 Alpha Research Group, Llc Compositions and methods for the treatment of parkinson's disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BENAZZI F: "PARKINSON'S DISEASE WORSENED BY NEFAZODONE", INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, JOHN WILEY AND SONS, CHICHESTER, GB, vol. 12, no. 12, 1 December 1997 (1997-12-01), pages 1195, XP008020678, ISSN: 0885-6230 *
HAUSER R A ET AL: "SERTRALINE FOR THE TREATMENT OF DEPRESSION IN PARKINSON'S DISEASE", MOVEMENT DISORDERS, RAVEN PRESS, NEW YORK, NY, US, vol. 12, no. 5, 1 September 1997 (1997-09-01), pages 756 - 759, XP009040237, ISSN: 0885-3185 *
KORPELAINEN J T ET AL: "MOCLOBEMIDE-INDUCED HYPERSEXUALITY IN PATIENTS WITH STROKE AND PARKINSON'S DISEASE", CLINICAL NEUROPHARMACOLOGY, RAVEN PRESS, NEW YORK, NY, US, vol. 21, no. 4, 1 July 1998 (1998-07-01), pages 251 - 254, XP000921343, ISSN: 0362-5664 *
SIMONS J A: "FLUOXETINE IN PARKINSON'S DISEASE", MOVEMENT DISORDERS, RAVEN PRESS, NEW YORK, NY, US, vol. 11, no. 5, 1 September 1996 (1996-09-01), pages 581/582, XP000670725, ISSN: 0885-3185 *

Also Published As

Publication number Publication date
EP1581167A2 (en) 2005-10-05
AU2003248893A1 (en) 2004-01-23
WO2004004660A2 (en) 2004-01-15
JP2006514917A (ja) 2006-05-18
CA2531810A1 (en) 2004-01-15
AU2003248893A8 (en) 2004-01-23
WO2004004660A3 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
IL175529A0 (en) Methods and compositions for the treatment of metabolic disorders
IL165950A0 (en) Compositions and method for the diagnosis and treatment of tumor
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
EP1680145A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
ZA200605555B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular disease
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003248660A1 (en) Treatment of vascular dysfunction and alzheimer's disease
AU2003248893A8 (en) Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias
IL166062A0 (en) Compositions and methods for therapeutic treatment
EP1539100A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
AU2003230848A1 (en) Methods and compositions for treating alzheimer's disease
AU2003277298A8 (en) Pharmaceutical compositions for treatment of parkinson's disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050603

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/47 A

A4 Supplementary search report drawn up and despatched

Effective date: 20081001

17Q First examination report despatched

Effective date: 20100215

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100202